NexMed (NEXM) Announces New Additional Patent Coverage for Israel
NexMed, Inc. (Nasdaq: NEXM) announced that the Israel Patent Office has issued an allowance notice for NexMed's patent application entitled, "Topical Compositions for Prostaglandin E1 Delivery."
The patent, when issued, will provide coverage to May 13, 2019, and expand the protection of NexMed’s Prostaglandin E1 (alprostadil)-based products in Israel to seven granted patents. NexMed has several alprostadil-based treatments under development, including Vitaros, for the treatment of erectile dysfunction; Femprox, for female sexual arousal disorder, and RayVa™, for Raynaud’s syndrome.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
The patent, when issued, will provide coverage to May 13, 2019, and expand the protection of NexMed’s Prostaglandin E1 (alprostadil)-based products in Israel to seven granted patents. NexMed has several alprostadil-based treatments under development, including Vitaros, for the treatment of erectile dysfunction; Femprox, for female sexual arousal disorder, and RayVa™, for Raynaud’s syndrome.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Dow Chemical (DOW) Wins $2.16B in K-Dow Arbitration
- Apple's (AAPL) New iPad Shows Rapid Adoption in U.S.
- Apple (AAPL) Amends RSU Award Agreements in Lieu of Upcoming Dividend; CEO Cook Defers
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
